Key points are not available for this paper at this time.
Molidustat maintained Hb levels throughout the trial in patients receiving dialysis and previously treated with erythropoiesis-stimulating agents, and was noninferior to darbepoetin.
Akizawa et al. (Fri,) studied this question.